AN-9 sensitivity of doxorubicin-resistant tumor cells
| Cells . | AN-9 IC50, μM . | doxorubicin IC50, μM . |
|---|---|---|
| HL60 | 52 ± 5.6 | 0.002 |
| HL60/ADR* | 57.3 ± 10.7 | > 2.0 |
| Diagnosed T-ALL | 50 | > 2.0 |
| Relapsed AML | 50 | > 5.0 |
| Be2c | 69.4 ± 8.4 | 0.007 |
| Be2c/ADR† | 70.7 ± 6.2 | > 2.0 |
| Cells . | AN-9 IC50, μM . | doxorubicin IC50, μM . |
|---|---|---|
| HL60 | 52 ± 5.6 | 0.002 |
| HL60/ADR* | 57.3 ± 10.7 | > 2.0 |
| Diagnosed T-ALL | 50 | > 2.0 |
| Relapsed AML | 50 | > 5.0 |
| Be2c | 69.4 ± 8.4 | 0.007 |
| Be2c/ADR† | 70.7 ± 6.2 | > 2.0 |
AN-9 IC50 in cell lines is an average from 2 independent experiments. Errors represent standard error of the mean. doxorubicin IC50 in cell lines is representative of that determined in at least 2 independent experiments. All conditions were performed in triplicate.
HL60/ADR was obtained by transfection of HL60 with theMDR-1 gene.
Be2c/ADR was obtained by selection of Be2c/ADR in doxorubicin-containing medium.